Jazz Pharmaceuticals (JAZZ) PT Raised to $201 at BMO Capital
May 9, 2018 6:45 AM
BMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $201.00 (from $199.00) while maintaining an Outperform rating.Analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
